Nanomedicine is a key player in cross-sectoral and cross-technological solutions for the diagnosis and treatment of superficial cancers like skin, breast, head and neck cancers, among many others. The unique properties of nanoparticles as drug carriers or electrical, mechanical, acoustic or even optical systems open new opportunities alone or when combined with other technologies. Several examples of cross-technological solutions will be covered by this Research Topic, and these will include advances in photothermal and photodynamic therapies combined with nanotechnological approaches. Advances in drug carriers based on nanoparticles will also be covered, some of which will include targeting moieties.
Depending on their location, grade and stage, cancers are treated with a combination of surgery, radiotherapy, phototherapy and photodynamic therapy, chemotherapy and/or immunotherapy. The strategic directions outlined in this collection aim to streamline translational cancer nanomedicine research and they will help to promote the clinical impact and performance of nanomedicine:
- Fundamental research of nanotechnologies applied to superficial cancers (development and characterization of nanosystems)
- Efficacy and safety assessment of developed nanosystems for superficial cancers using different live organisms (preferably two models)
- Translation of the developed nanosystems
- Inputs on scalable manufacturing protocols and regulatory processes that will enrich the discussion on the development and potentiality of such nanosystems.
The cancer nanomedicine field has expanded exponentially in recent years. In contrast to the numerous new materials and papers that are being produced, only about fifty nanomedicines have thus far made it to the market. To change this situation, we must move away from continuously making increasingly new materials and critically reconsider how we are doing translational cancer nanomedicine research. We must establish smart strategies to make nanomedicines work in as many live organisms as possible. This shift requires rational and realistic thinking, and integrated and concerted efforts from consortia comprising academics, clinicians, pharmaceutical companies and regulatory authorities. Original research, systematic review, methods, reviews or mini-reviews and clinical trials are very welcome.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Nanomedicine is a key player in cross-sectoral and cross-technological solutions for the diagnosis and treatment of superficial cancers like skin, breast, head and neck cancers, among many others. The unique properties of nanoparticles as drug carriers or electrical, mechanical, acoustic or even optical systems open new opportunities alone or when combined with other technologies. Several examples of cross-technological solutions will be covered by this Research Topic, and these will include advances in photothermal and photodynamic therapies combined with nanotechnological approaches. Advances in drug carriers based on nanoparticles will also be covered, some of which will include targeting moieties.
Depending on their location, grade and stage, cancers are treated with a combination of surgery, radiotherapy, phototherapy and photodynamic therapy, chemotherapy and/or immunotherapy. The strategic directions outlined in this collection aim to streamline translational cancer nanomedicine research and they will help to promote the clinical impact and performance of nanomedicine:
- Fundamental research of nanotechnologies applied to superficial cancers (development and characterization of nanosystems)
- Efficacy and safety assessment of developed nanosystems for superficial cancers using different live organisms (preferably two models)
- Translation of the developed nanosystems
- Inputs on scalable manufacturing protocols and regulatory processes that will enrich the discussion on the development and potentiality of such nanosystems.
The cancer nanomedicine field has expanded exponentially in recent years. In contrast to the numerous new materials and papers that are being produced, only about fifty nanomedicines have thus far made it to the market. To change this situation, we must move away from continuously making increasingly new materials and critically reconsider how we are doing translational cancer nanomedicine research. We must establish smart strategies to make nanomedicines work in as many live organisms as possible. This shift requires rational and realistic thinking, and integrated and concerted efforts from consortia comprising academics, clinicians, pharmaceutical companies and regulatory authorities. Original research, systematic review, methods, reviews or mini-reviews and clinical trials are very welcome.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
